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with the physician/Less than 6 months of survival/Intravenous
administration). The factors that inﬂuence more on the treatment
preferences were, symptoms’ control (31% of the patients), con-
ﬁdence with the physician (21.6%) and immediate toxicity
(18.7%). CONCLUSION: Through a conjoint analysis we may
conclude that the most important attributes for the patients were
symptoms’ control followed by conﬁdence with their physician.
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OBJECTIVES: Sunitinib malate is an oral, tyrosine kinase inhibi-
tor that targets VEGFRs, PDGFRs, KIT, RET and FLT3, with
antitumour and antiangiogenic effects. Sunitinib demonstrated
statistically superior efﬁcacy and HRQOL over IFN-alfa as ﬁrst-
line mRCC therapy (P < 0.001) in an international, randomised
phase III trial [Motzer et al. NEJM 2007;356:115–24]. These
analyses examine the association between geography and treat-
ment effect on patient-reported outcomes (PROs). METHODS:
Patients with mRCC (N = 750) were randomised 1 : 1 to suni-
tinib 50 mg/day orally in 6-week cycles (4 weeks on, 2 weeks off)
or IFN-alfa (9 MU SC TIW). HRQOL was assessed on days 1
and 28 of each cycle using the following instruments: 1) FACT-
Kidney Symptom Index (FKSI) and its disease-related symptom
subscale (FKSI-DRS); 2) Functional Assessment of Cancer
Therapy-General (FACT-G) and its 4 subscales; and 3)
population-preference-based health state utility score (EQ-5D
Index) and patient self-rated overall health state (EQ-VAS) from
the EQ-5D self-report questionnaire. Data were analysed using
repeated-measures mixed-effects models for the EU+ (France,
Germany, Italy, Poland, Russia, Spain, UK, plus Australia and
Canada; n = 400) and US (n = 346) subsamples. RESULTS: Suni-
tinib provided a signiﬁcant beneﬁt compared with IFN-alfa in
the overall post-baseline least-square means for in all 9 PRO
endpoints (P < 0.05), except EQ-5D in the US subsample
(P = 0.4105). Most of the 9 FKSI-DRS items also favoured suni-
tinib. These ﬁndings were consistent with the overall sample
results. Larger between-treatment differences were generally
observed in the EU+ subsample compared with the US sub-
sample. CONCLUSION: In both Europe and the US, sunitinib
offers consistent HRQOL and kidney cancer-related symptoms
advantages compared with IFN-alfa in the ﬁrst-line treatment of
mRCC. These advantages were more pronounced in the EU+
sample and may reﬂect differences in treatment experience or
underlying differences in HRQOL reporting.
PCN73
LINGUISTICVALIDATION OFTHE HOT FLASH DIARY FOR
PROSTATE CANCER PATIENTS IN EIGHT LANGUAGES FOR
NINE COUNTRIES
Eremenco S1,Arnold B1,Weinstein D2, Sendersky V2
1Evanston Northwestern Healthcare, Evanston, IL, USA,
2Ferring Pharmaceuticals, Copenhagen, Denmark
OBJECTIVES: Hot ﬂashes are important adverse effects of
androgen deprivation therapies (ADT) in prostate cancer
patients. The prevalence of hot ﬂashes in patients undergoing
ADT is approximately 70–80%. Fifty-ﬁve percent of patients
report distress due to their hot ﬂashes. The Hot Flash Diary
(HFD) developed by the North Central Cancer Treatment
Group/Mayo Clinic measures patient’s daily assessment of hot
ﬂash frequency and severity and enables calculation of a hot
ﬂash score. Severity is measured on a scale from 1 (“Mild”) to
4 (“Very severe”). To measure hot ﬂashes in prostate cancer
patients cross-culturally, we performed the translation/
adaptation and linguistic validation of the HFD for use in 9
countries: Canada (French/English), Czech Republic, France,
Germany, Hungary, The Netherlands, Spain (Catalan/Spanish),
US (Spanish), and UK. METHODS: The translation/adaptation
and linguistic validation of the HFD followed an established and
rigorous method to ensure conceptual equivalence between the
original and translated versions. The methodology consisted of
10 steps: 1) item deﬁnition development; 2) two forward trans-
lations; 3) reconciliation; 4) back-translation; 5) source and
back-translated text comparison; 6) bilingual expert review; 7)
ﬁnalization; 8) harmonization; 9) comprehension testing with
patients; and 10) post-testing review/revision. RESULTS: Lin-
guistic and conceptual issues were identiﬁed during translation. It
proved difﬁcult to ﬁnd precise equivalents for adjectives describ-
ing the degree of hot ﬂash (e.g. ‘mild’, ‘moderate’, ‘severe’) in
several languages. Additional problems were mainly related to
semantics and syntax. Overall, the HFD was well understood by
the patients and they encountered little difﬁculty in its comple-
tion. CONCLUSION: Linguistic validity of the HFD for 9 coun-
tries was conﬁrmed. International prostate cancer trials are
currently underway and cross-cultural data on hot ﬂashes will be
available to provide international comparison of this very both-
ersome adverse effect of ADT.
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OBJECTIVES: The Consequence of Screening in Breast Cancer
questionnaire (COS-BC) assesses the psychosocial consequences
of abnormal and false-positive screening mammography. It has
two parts; one covering the period between abnormal screening
and ﬁnal diagnosis and one relating to the period following being
declared free from cancer. The ﬁrst aim of the study was to assess
if COS (i.e. COS-BC without the breast speciﬁc items) was rel-
evant for persons having false-positive lung cancer screening
results. The second was to develop new items speciﬁcally relevant
to participants in lung cancer screening. METHODS: A ran-
domised study of lung cancer screening was launched in
Denmark in 2005. Five focus groups were held with 20 people
(13 women and 7 men; mean age 60.0 years) who had received
an abnormal screening result in the prevalence round and were
recalled for a scan after 3 months. They discussed their thoughts
and feelings after being recalled and after receiving the ﬁnal
false-positive diagnosis. They completed the COS and discussed
its relevance to their own experiences. The face and content
validity of new items developed after the focus groups was tested
by means of interviews with 6 participants from the focus groups
RESULTS: The items in the COS were all relevant for lung cancer
screening. Three themes were extracted from the audio-taped
interviews. Stigmatisation, Self-blame and Focus on symptoms.
Twenty-six new items for part I and 16 for part II of the ques-
tionnaire (COS-LC) were generated. CONCLUSION: There are
many common psychosocial consequences of abnormal and
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false-positive screening in breast cancer and lung cancer.
However, several new lung-speciﬁc items were needed to obtain
high content coverage and, consequently, make the COS-LC
relevant to lung cancer screening. The questionnaire is currently
in use in the Danish randomised study and will be validated using
Item Response Theory (the Rasch model).
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OBJECTIVES: The purpose is to prospectively describe factors
that may inﬂuence the choice between surgery, radiation, and
watchful waiting among men newly diagnosed with local stage
prostate cancer. METHODS: Beginning in December 2005, pros-
tate cancer patients were approached shortly after diagnosis at
urology clinics in Texas, California and South Carolina. Patients
took home a self-administered survey to complete as they made
their treatment decision. Preliminary data are available for 148
men with recruitment continuing through 2007. Logistic regres-
sion was used to identify factors associated with choice of treat-
ment. RESULTS: Overall 65% of men returned the survey before
starting treatment. A total of 82% indicated they were only
considering (or had considered) a single option; 64% were only
considering surgery, 9% were only considering radiation, 9%
were only considering non-curative therapies, and 18% were
considering multiple options or were unsure of their decision.
Being married (OR 4.7; 95% CI: 1.1, 19.4), being under age 70
(OR 2.7; 95% CI: 1.0, 7.0), and having an annual household
income higher than $60,000 (OR 2.9; 95% CI: 1.0, 8.1) were
strongly associated with considering surgery only. CONCLU-
SION: Understanding why most men feel their only option is
surgery is a priority to ensure that physician biases, patient
misperceptions, or fear do not lead patients to select procedures
that do not agree with their personal preferences. Many patients
appear to make rapid treatment decisions. Interventions to aid
treatment decision-making must target men soon after they
receive their diagnosis.
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OBJECTIVES: To measure and compare preferences for
attributes of colorectal cancer (CRC) screening tests using a
stated preference survey of the general population and physicians
in Canada and the United States (US). METHODS: A stated
preference survey was administered online with 11 choice tasks
between two hypothetical CRC screening tests. Each test was
described by nine attributes: process, pain, preparation, fre-
quency, follow-up, complication risk, sensitivity, speciﬁcity, and
out-of-pocket cost. Each scenario included a follow-up opt-out
question to choose no screening. A total of 1087 US and
501 Canadian respondents participated and 100 physicians
responded in both countries. Physicians were asked to indicate
their patients’ preferences. Responses were modeled using bivari-
ate regression with main effects and interactions with the optout
term. Willingness-to-pay was calculated for common CRC
screening tests. RESULTS: Physicians expected patients to choose
the option of ’no screening’ more frequently than patients them-
selves (55% vs 29% respectively, p < 0.001). For all groups the
most important attribute was sensitivity, but physicians’ percep-
tion of patients’ preferences were signiﬁcantly different from
actual patient preferences. Other key attributes were those
related to test performance or the testing process. Fecal DNA,
colonoscopy, and virtual colonoscopy were the most preferred
tests by all groups, but respondents were willing-to-pay more
than physicians predicted. CONCLUSION: Physicians’ percep-
tion of patients’ preferences are signiﬁcantly different from those
of the general population, although both preferred tests with
high sensitivity. The signiﬁcant difference in the frequency of
choosing no screening between physicians and their patients may
have serious implications for CRC screening uptake since physi-
cians generally exert a strong inﬂuence on decisions about health
care treatment, and especially screening programs. Among
general population and physicians, Canadian and US respon-
dents’ preferences were similar.
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OBJECTIVES: Intra-ocular pressure (IOP) ﬂuctuation over 24
hours is an independent risk factor for glaucoma progression.
Night-time IOP measurement is not a routine practice. The aim
of this study was to predict the risk of a nocturnal IOP peak from
day-time measurements. METHODS: IOP measurements from
three clinical trials were pooled. The night-time IOP peak was
deﬁned as the maximum value observed between 00:00 h and
04:00 h. IOP measurements at 08:00 h, 12:00 h, 16:00 h, and
20:00 h were dichotomized using four thresholds: 15, 18, 21,
and 25 mmHg. Patient IOPs were assessed during pre-treatment
washout periods and after treatment with a prostaglandin ana-
logue (PGA: latanoprost or travoprost). A Bayesian network
(BN), adjusted for trial effects, was constructed to study the
association between day-time IOP, nocturnal IOP, and treatment
effects at each of the four thresholds. RESULTS: In total, 382
daily IOP vectors were identiﬁed (pre-treatment: 208; PGA: 174).
The BN association structures differed according to threshold
value. A direct drug effect on the night peak associated with IOP
control at 12:00 was required for a 15 mmHg night IOP target.
Control of IOP at 12:00 and 20:00 was associated with night
control for an 18 mmHg target, at 8:00 and 20:00 for 21 and
25 mmHg targets. Both PGAs were effective in controlling night-
time IOP after it was controlled during the day. Night-time IOP
responder rate differences (pre-treatment minus treatment) pre-
dicted by the BN were 28.7% for the 15 mmHg target, 44.9%
for the 18 mmHg target, 54.0% for the 21 mmHg target, and
9.4% for the 25 mmHg target. CONCLUSION: Day-time IOP
measurements are highly inter-correlated and BNs can help to
predict nocturnal IOP control from day-time measurements. BN
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